By Helgi Library - May 21, 2023
Dr.Max made a net profit of CZK 762 mil with revenues of CZK 24,796 mil in 2022, up by 31.7% and up by 9.88%, respe...
By Helgi Library - May 21, 2023
Dr.Max made a net profit of CZK 762 mil with revenues of CZK 24,796 mil in 2022, up by 31.7% and up by 9.88%, respe...
By Helgi Library - May 21, 2023
Dr.Max made a net profit of CZK 762 mil in 2022, up 31.7% compared to the previous year. Total sales reached CZK 24,796 mil, whi...
| Profit Statement | 2020 | 2021 | 2022 | |
| Sales | CZK mil | 21,098 | 22,566 | 24,796 |
| Gross Profit | CZK mil | 4,266 | 4,482 | 4,967 |
| EBITDA | CZK mil | 1,393 | 1,469 | 1,702 |
| EBIT | CZK mil | 1,009 | 1,024 | 1,242 |
| Financing Cost | CZK mil | 237 | 219 | 297 |
| Pre-Tax Profit | CZK mil | 694 | 770 | 1,007 |
| Net Profit | CZK mil | 518 | 579 | 762 |
| Balance Sheet | 2020 | 2021 | 2022 | |
| Total Assets | CZK mil | 14,560 | 15,483 | 19,353 |
| Non-Current Assets | CZK mil | 10,038 | 9,808 | 9,772 |
| Current Assets | CZK mil | 4,372 | 5,534 | 9,435 |
| Working Capital | CZK mil | 77.0 | 290 | 4,254 |
| Shareholders' Equity | CZK mil | 4,837 | 5,118 | 6,055 |
| Liabilities | CZK mil | 9,724 | 10,365 | 13,298 |
| Total Debt | CZK mil | 5,775 | 5,398 | 7,695 |
| Net Debt | CZK mil | 5,108 | 4,316 | 7,055 |
| Ratios | 2020 | 2021 | 2022 | |
| ROE | % | 11.6 | 11.6 | 13.6 |
| ROCE | % | 5.05 | 5.73 | 6.32 |
| Gross Margin | % | 20.2 | 19.9 | 20.0 |
| EBITDA Margin | % | 6.60 | 6.51 | 6.86 |
| EBIT Margin | % | 4.78 | 4.54 | 5.01 |
| Net Margin | % | 2.46 | 2.57 | 3.07 |
| Net Debt/EBITDA | 3.67 | 2.94 | 4.15 | |
| Net Debt/Equity | % | 106 | 84.3 | 117 |
| Cost of Financing | % | 3.99 | 3.91 | 4.53 |
| Cash Flow | 2020 | 2021 | 2022 | |
| Total Cash From Operations | CZK mil | 910 | 1,761 | 1,307 |
| Total Cash From Investing | CZK mil | 6.95 | -293 | -2,890 |
| Total Cash From Financing | CZK mil | -343 | -1,278 | 1,003 |
| Net Change In Cash | CZK mil | 574 | 189 | -581 |
| Cash Conversion Cycle | days | -7.07 | -6.07 | 51.4 |
| Cash Earnings | CZK mil | 902 | 1,023 | 1,222 |
| Free Cash Flow | CZK mil | 917 | 1,468 | -1,584 |
Get all company financials in excel:
| overview | Unit | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
| income statement | |||||||||||
| Sales | CZK mil | 14,895 | 16,108 | 17,949 | 20,015 | 21,098 | |||||
| Gross Profit | CZK mil | 2,809 | 3,048 | 3,387 | 4,011 | 4,266 | |||||
| EBIT | CZK mil | 802 | 578 | 572 | 928 | 1,009 | |||||
| Net Profit | CZK mil | 238 | 132 | 108 | 485 | 518 | |||||
| ROE | % | ... | 16.3 | 7.15 | 3.85 | 12.3 | 11.6 | ||||
| EBIT Margin | % | 5.39 | 3.59 | 3.19 | 4.64 | 4.78 | |||||
| Net Margin | % | 1.60 | 0.821 | 0.603 | 2.42 | 2.46 | |||||
| Employees | 2,838 | 3,084 | 3,323 | 3,589 | 3,926 | ||||||
| balance sheet | |||||||||||
| Total Assets | CZK mil | 13,123 | 13,660 | 13,921 | 14,200 | 14,560 | |||||
| Non-Current Assets | CZK mil | 10,220 | 10,261 | 10,249 | 10,269 | 10,038 | |||||
| Current Assets | CZK mil | 2,716 | 3,226 | 3,500 | 3,760 | 4,372 | |||||
| Shareholders' Equity | CZK mil | 1,820 | 1,879 | 3,737 | 4,118 | 4,837 | |||||
| Liabilities | CZK mil | 11,302 | 11,781 | 10,183 | 10,082 | 9,724 | |||||
| Non-Current Liabilities | CZK mil | 7,880 | 7,808 | 6,023 | 5,701 | 5,380 | |||||
| Current Liabilities | CZK mil | 3,171 | 3,725 | 3,951 | 4,066 | 4,179 | |||||
| Net Debt/EBITDA | 8.50 | 8.68 | 6.44 | 5.03 | 3.67 | ||||||
| Net Debt/Equity | % | 444 | 412 | 159 | 141 | 106 | |||||
| Cost of Financing | % | ... | 5.51 | 4.14 | 4.53 | 4.66 | 3.99 | ||||
| cash flow | |||||||||||
| Total Cash From Operations | CZK mil | 629 | 932 | -450 | 826 | 910 | |||||
| Total Cash From Investing | CZK mil | -201 | -361 | -331 | -526 | 6.95 | |||||
| Total Cash From Financing | CZK mil | -354 | -352 | 721 | -346 | -343 | |||||
| Net Change In Cash | CZK mil | 74.1 | 219 | -60.7 | -45.6 | 574 |
| income statement | Unit | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
| income statement | |||||||||||
| Sales | CZK mil | 14,895 | 16,108 | 17,949 | 20,015 | 21,098 | |||||
| Cost of Goods & Services | CZK mil | 12,085 | 13,061 | 14,562 | 16,005 | 16,832 | |||||
| Gross Profit | CZK mil | 2,809 | 3,048 | 3,387 | 4,011 | 4,266 | |||||
| Staff Cost | CZK mil | 1,843 | 2,175 | 2,524 | 2,839 | 2,922 | |||||
| EBITDA | CZK mil | 951 | 892 | 921 | 1,155 | 1,393 | |||||
| Depreciation | CZK mil | 148 | 314 | 349 | 227 | 384 | |||||
| EBIT | CZK mil | 802 | 578 | 572 | 928 | 1,009 | |||||
| Net Financing Cost | CZK mil | 506 | 378 | 403 | 336 | 315 | |||||
| Financing Cost | CZK mil | 473 | 340 | 329 | 290 | 237 | |||||
| Financing Income | CZK mil | 0.392 | 0.267 | 0.295 | 0.231 | 0.385 | |||||
| Extraordinary Cost | CZK mil | 0 | 0 | 0 | 0 | 0 | |||||
| Pre-Tax Profit | CZK mil | 296 | 200 | 169 | 592 | 694 | |||||
| Tax | CZK mil | 58.4 | 67.8 | 61.0 | 107 | 175 | |||||
| Minorities | CZK mil | 0 | 0 | 0 | 0 | 0 | |||||
| Net Profit | CZK mil | 238 | 132 | 108 | 485 | 518 | |||||
| Net Profit Avail. to Common | CZK mil | 238 | 132 | 108 | 485 | 518 | |||||
| growth rates | |||||||||||
| Total Revenue Growth | % | ... | 5.23 | 8.15 | 11.4 | 11.5 | 5.41 | ||||
| Staff Cost Growth | % | ... | 9.32 | 18.1 | 16.0 | 12.4 | 2.93 | ||||
| EBITDA Growth | % | ... | 2.21 | -6.17 | 3.23 | 25.4 | 20.6 | ||||
| EBIT Growth | % | ... | 86.1 | -28.0 | -0.959 | 62.2 | 8.71 | ||||
| Pre-Tax Profit Growth | % | ... | -314 | -32.5 | -15.5 | 250 | 17.1 | ||||
| Net Profit Growth | % | ... | -227 | -44.4 | -18.2 | 348 | 6.89 | ||||
| ratios | |||||||||||
| ROE | % | ... | 16.3 | 7.15 | 3.85 | 12.3 | 11.6 | ||||
| ROA | % | ... | 1.83 | 0.988 | 0.784 | 3.45 | 3.60 | ||||
| ROCE | % | ... | 2.32 | 1.29 | 1.06 | 4.69 | 5.05 | ||||
| Gross Margin | % | 18.9 | 18.9 | 18.9 | 20.0 | 20.2 | |||||
| EBITDA Margin | % | 6.38 | 5.54 | 5.13 | 5.77 | 6.60 | |||||
| EBIT Margin | % | 5.39 | 3.59 | 3.19 | 4.64 | 4.78 | |||||
| Net Margin | % | 1.60 | 0.821 | 0.603 | 2.42 | 2.46 | |||||
| Cost of Financing | % | ... | 5.51 | 4.14 | 4.53 | 4.66 | 3.99 | ||||
| Net Debt/EBITDA | 8.50 | 8.68 | 6.44 | 5.03 | 3.67 |
| balance sheet | Unit | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
| balance sheet | |||||||||||
| Cash & Cash Equivalents | CZK mil | 177 | 395 | 335 | 289 | 663 | |||||
| Receivables | CZK mil | 1,315 | 1,584 | 1,838 | 2,001 | 1,992 | |||||
| Inventories | CZK mil | 1,225 | 1,246 | 1,328 | 1,470 | 1,517 | |||||
| Current Assets | CZK mil | 2,716 | 3,226 | 3,500 | 3,760 | 4,372 | |||||
| Property, Plant & Equipment | CZK mil | 413 | 588 | 614 | 693 | 647 | |||||
| LT Investments & Receivables | CZK mil | 13.3 | 15.8 | 94.0 | 3.00 | 3.10 | |||||
| Intangible Assets | CZK mil | 9,793 | 9,658 | 9,541 | 9,574 | 9,388 | |||||
| Goodwill | CZK mil | 9,793 | 9,603 | 9,466 | 9,466 | 9,287 | |||||
| Non-Current Assets | CZK mil | 10,220 | 10,261 | 10,249 | 10,269 | 10,038 | |||||
| Total Assets | CZK mil | 13,123 | 13,660 | 13,921 | 14,200 | 14,560 | |||||
| Trade Payables | CZK mil | 2,445 | 2,896 | 3,133 | 3,333 | 3,432 | |||||
| Short-Term Debt | CZK mil | 390 | 351 | 337 | 395 | 395 | |||||
| Other ST Liabilities | CZK mil | 336 | 478 | 481 | 338 | 352 | |||||
| Current Liabilities | CZK mil | 3,171 | 3,725 | 3,951 | 4,066 | 4,179 | |||||
| Long-Term Debt | CZK mil | 7,879 | 7,807 | 6,023 | 5,701 | 5,379 | |||||
| Other LT Liabilities | CZK mil | 1.36 | 0.500 | 0.500 | 0 | 0.074 | |||||
| Non-Current Liabilities | CZK mil | 7,880 | 7,808 | 6,023 | 5,701 | 5,380 | |||||
| Liabilities | CZK mil | 11,302 | 11,781 | 10,183 | 10,082 | 9,724 | |||||
| Equity Before Minority Interest | CZK mil | 1,820 | 1,879 | 3,737 | 4,118 | 4,837 | |||||
| Minority Interest | CZK mil | 0 | 0 | 0 | 0 | 0 | |||||
| Equity | CZK mil | 1,820 | 1,879 | 3,737 | 4,118 | 4,837 | |||||
| growth rates | |||||||||||
| Total Asset Growth | % | ... | 1.72 | 4.09 | 1.91 | 2.01 | 2.54 | ||||
| Shareholders' Equity Growth | % | ... | 66.1 | 3.25 | 98.9 | 10.2 | 17.4 | ||||
| Net Debt Growth | % | ... | -8.00 | -4.10 | -23.4 | -2.13 | -12.0 | ||||
| Total Debt Growth | % | ... | -6.98 | -1.33 | -22.0 | -4.14 | -5.28 | ||||
| ratios | |||||||||||
| Total Debt | CZK mil | 8,268 | 8,158 | 6,360 | 6,097 | 5,775 | |||||
| Net Debt | CZK mil | 8,079 | 7,747 | 5,931 | 5,805 | 5,108 | |||||
| Working Capital | CZK mil | 94.6 | -66.1 | 32.1 | 138 | 77.0 | |||||
| Capital Employed | CZK mil | 10,314 | 10,195 | 10,281 | 10,408 | 10,115 | |||||
| Net Debt/Equity | % | 444 | 412 | 159 | 141 | 106 | |||||
| Current Ratio | 0.857 | 0.866 | 0.886 | 0.925 | 1.05 | ||||||
| Quick Ratio | 0.470 | 0.531 | 0.550 | 0.563 | 0.635 |
| cash flow | Unit | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
| cash flow | |||||||||||
| Net Profit | CZK mil | 238 | 132 | 108 | 485 | 518 | |||||
| Depreciation | CZK mil | 148 | 314 | 349 | 227 | 384 | |||||
| Non-Cash Items | CZK mil | ... | 300 | 324 | -809 | 220 | -53.7 | ||||
| Change in Working Capital | CZK mil | ... | -57.4 | 161 | -98.2 | -106 | 61.2 | ||||
| Total Cash From Operations | CZK mil | 629 | 932 | -450 | 826 | 910 | |||||
| Capital Expenditures | CZK mil | -205 | -368 | -336 | -318 | -195 | |||||
| Other Investing Activities | CZK mil | 4.45 | 7.02 | 5.10 | -208 | 202 | |||||
| Total Cash From Investing | CZK mil | -201 | -361 | -331 | -526 | 6.95 | |||||
| Dividends Paid | CZK mil | 0 | 0 | 0 | 0 | 0 | |||||
| Issuance Of Shares | CZK mil | 0 | 0 | 2,150 | 0 | 0 | |||||
| Issuance Of Debt | CZK mil | -354 | -352 | 1,350 | -346 | -322 | |||||
| Total Cash From Financing | CZK mil | -354 | -352 | 721 | -346 | -343 | |||||
| Net Change In Cash | CZK mil | 74.1 | 219 | -60.7 | -45.6 | 574 | |||||
| ratios | |||||||||||
| Days Sales Outstanding | days | 32.2 | 35.9 | 37.4 | 36.5 | 34.5 | |||||
| Days Sales Of Inventory | days | 37.0 | 34.8 | 33.3 | 33.5 | 32.9 | |||||
| Days Payable Outstanding | days | 73.8 | 80.9 | 78.5 | 76.0 | 74.4 | |||||
| Cash Conversion Cycle | days | -4.63 | -10.2 | -7.89 | -5.99 | -7.07 | |||||
| Cash Earnings | CZK mil | 386 | 446 | 457 | 712 | 902 | |||||
| Free Cash Flow | CZK mil | 428 | 571 | -782 | 300 | 917 | |||||
| Capital Expenditures (As % of Sales) | % | 1.38 | 2.28 | 1.87 | 1.59 | 0.922 |
| other ratios | Unit | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
| Employees | 2,838 | 3,084 | 3,323 | 3,589 | 3,926 | ||||||
| Cost Per Employee | USD per month | 2,144 | 2,505 | 2,894 | 2,924 | 2,818 | |||||
| Cost Per Employee (Local Currency) | CZK per month | 54,105 | 58,784 | 63,306 | 65,910 | 62,016 | |||||
| Material & Energy (As % of Sales) | % | 71.9 | 71.5 | 71.7 | 70.8 | 70.4 | |||||
| Services (As % of Sales) | % | 9.21 | 9.55 | 9.43 | 9.12 | 9.39 | |||||
| Marketing Cost (As % of Sales) | % | 1.76 | 1.83 | 1.74 | 1.78 | 1.58 | |||||
| Staff Cost (As % of Sales) | % | 12.4 | 13.5 | 14.1 | 14.2 | 13.8 | |||||
| Effective Tax Rate | % | 19.7 | 33.9 | 36.1 | 18.1 | 25.3 | |||||
| Total Revenue Growth (5-year average) | % | ... | ... | ... | ... | ... | 7.33 | 10.2 | 8.31 | ||
| Branches | ... | ... | ... | ... | ... | ... | ... | ... |
Get all company financials in excel:
By Helgi Library - May 21, 2023
Dr.Max made a net profit of CZK 762 mil in 2022, up 31.7% compared to the previous year. Total sales reached CZK 24,796 mil, which is up 9.88% when compared to the previous year. Historically, between 2013 and 2022, the company’s net profit reached...
By Helgi Library - May 21, 2023
Dr.Max employed 4,063 employees in 2022, up 4.53% compared to the previous year. Historically, between 2013 and 2022, the firm's workforce hit a high of 4,063 employees in 2022 and a low of 2,221 employees in 2013. Average personnel cost stood at USD...
By Helgi Library - May 21, 2023
Dr.Max employed 4,063 employees in 2022, up 4.53% compared to the previous year. Historically, between 2013 and 2022, the firm's workforce hit a high of 4,063 employees in 2022 and a low of 2,221 employees in 2013. Average personnel cost stood at USD...
By Helgi Library - May 21, 2023
Dr.Max's net debt stood at CZK 7,055 mil and accounted for 117% of equity at the end of 2022. The ratio is up 32.2 pp compared to the previous year. Historically, the firm’s net debt to equity reached a high of 801% in 2015 and a low of 23.8%...
By Helgi Library - May 21, 2023
Dr.Max's net debt stood at CZK 7,055 mil and accounted for 117% of equity at the end of 2022. The ratio is up 32.2 pp compared to the previous year. Historically, the firm’s net debt to equity reached a high of 801% in 2015 and a low of 23.8%...
By Helgi Library - May 21, 2023
Dr.Max made a net profit of CZK 762 mil in 2022, up 31.7% compared to the previous year. Historically, between 2013 and 2022, the company's net profit reached a high of CZK 828 mil in 2014 and a low of CZK -187 mil in 2015. The result implies a return on ...
By Helgi Library - May 21, 2023
Dr.Max made a net profit of CZK 762 mil in 2022, up 31.7% compared to the previous year. Historically, between 2013 and 2022, the company's net profit reached a high of CZK 828 mil in 2014 and a low of CZK -187 mil in 2015. The result implies a return on ...
By Helgi Library - May 21, 2023
Dr.Max invested a total of CZK 420 mil in 2022, up 30.7% compared to the previous year. Historically, between 2013 - 2022, the company's investments stood at a high of CZK 420 mil in 2022 and a low of CZK 76.4 mil in 2015. As a percen...
By Helgi Library - May 21, 2023
Dr.Max invested a total of CZK 420 mil in 2022, up 30.7% compared to the previous year. Historically, between 2013 - 2022, the company's investments stood at a high of CZK 420 mil in 2022 and a low of CZK 76.4 mil in 2015. As a percen...
By Helgi Library - May 21, 2023
Dr.Max made a net profit of CZK 762 mil with revenues of CZK 24,796 mil in 2022, up by 31.7% and up by 9.88%, respectively, compared to the previous year. This translates into a net margin of 3.07%. Historically, between 2013 and 2022, the firm’s ...
Dr.Max Czech is a Czech Republic-based operator of pharmacy stores. Its pharmacies are located in department stores, hospitals, clinics, historical city centers and commercial shopping stores. The company also operates as a pharmaceutical wholesaler in the Czech Republic. It was founded in 2002 and is headquartered in Brno, Czech Republic. Dr. Max Group is fully owned by Penta Investments, an investment group.
Dr.Max has been growing its sales by 9.01% a year on average in the last 5 years. EBITDA has grown on average by 13.8% a year during that time to total of CZK 1,702 mil in 2022, or 6.86% of sales. That’s compared to 6.17% average margin seen in last five years.
The company netted CZK 762 mil in 2022 implying ROE of 13.6% and ROCE of 6.32%. Again, the average figures were 10.6% and 4.57%, respectively when looking at the previous 5 years.
Dr.Max’s net debt amounted to CZK 7,055 mil at the end of 2022, or 117% of equity. When compared to EBITDA, net debt was 4.15x, down when compared to average of 4.44x seen in the last 5 years.
Helgi Library 
